Publications

Selected Publications

Xu A, Haro M, Walts AE, Karlan BY, Merchant A, Orsulic S. Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma. Science Advances 2024; 10(16):eadk8805.

Hu Y, Recouvreux MS, Haro M, Taylan E, Taylor-Harding B, Walts AE, Karlan BY, Orsulic S. INHBA(+) cancer-associated fibroblasts generate an immunosuppressive tumor microenvironment in ovarian cancer. npj Precision Oncology 2024; 15;8(1):35.

Broz MT, Ko EY, Ishaya K, Xiao J, De Simone M, Hoi XP, Piras R, Gala B, Tessaro FHG, Karlstaedt A, Orsulic S, Lund AW, Chan KS, Guarnerio J. Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas. Nature Communications 2024; 15(1):2498.

Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S, Laco J, Ryska A, Dundr P, Kocian R, Brtnicky T, Skapa P, Capkova L, Kovar M, Prochazka J, Praznovec I, Koblizek V, Taskova A, Tanaka H, Lischke R, Mendez FC, Vachtenheim J Jr, Heinzelmann-Schwarz V, Jacob F, McNeish IA, Halaska MJ, Rob L, Cibula D, Orsulic S, Galluzzi L, Spisek R, Fucikova J. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nature Communications 2024; 15(1):2528.

Cheon D-J, Tong Y, Cim M-S, Dering J, Berel D, Cui X, Lester J, Tighiouart M, Walts AE, Karlan BY, Orsulic S.  A collagen-remodeling gene signature regulated by TGFβ signaling is associated with metastasis and overall survival in serous ovarian cancer.  Clinical Cancer Research 2014; 20:711-723.

Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia S, Sharp PA.  Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.  PNAS 2010; 108:745-750.

Xing D, Scangas G, Nita M, He L, Xu X, Ioffe YJM, Aspuria P-J, Hedvat CY, Anderson ML, Oliva E, Karlan BY, Mohapatra G, Orsulic S.  A role for BRCA1 in uterine leiomyosarcoma.  Cancer Research 2009; 69:8231-8235.

Miao J, Wang Z, Provencher H, Muir B, Dahiya S, Carney E, Leong C-O, Sgroi DC, Orsulic S.  HOXB13 induces ovarian cancer progression.  PNAS 2007; 104:17093-17098.

Xing D, Orsulic S.  A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.  PNAS 2005; 102:6939-6941.

Xing D, Orsulic S.  A mouse model for the molecular characterization of BRCA1-associated ovarian carcinoma.  Cancer Research 2006; 18:8949-8953 (Featured article and sidebar photo).

Gasser S, Orsulic S, Brown E, Raulet D.  The DNA damage pathway regulates innate immune system ligands for the NKG2D receptor.  Nature 2005; 436:1186-1190. (Featured article).

Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind SJ, Varmus HE.  Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.  Cancer Cell 2002; 1:53-62. (Featured article review in the same issue of Cancer Cell: Of Mice and Women; featured article in Nature Reviews Cancer: A First for Ovarian Cancer).